Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Theravance has reported revenues of $5.3m for the third quarter ended 30 September 2010, compared to $5.52m for the same period in 2009.
Subscribe to our email newsletter
Theravance has posted a net loss of $21.22m for the third quarter 2010, or $0.29 loss per diluted share, compared to a net loss of $22.18m, or $0.35 loss per diluted share, for the comparable period in 2009.
Loss from operations was $19.85m, compared to $21.08m for the comparable period in 2009.
For the nine months ended 30 September 2010, Theravance has posted a revenue of $17.28m, compared to $20.55m for the year ago period.
For the nine months ended 30 September 2010, Theravance has posted a net loss of $64.56m, or $0.91 loss per diluted share, compared to net loss of $63.09m, or $1 loss per diluted share, for the year ago period.
Loss from operations was $60.39m, compared to $60.78m for the year ago period.
Theravance CEO Rick Winningham said that the Relovair Phase 3 programs in COPD and asthma are progressing well and have now enrolled over 8,000 patients.
Theravance is a biopharmaceutical company focused on the discovery, development and commercialisation of small molecule medicines across a number of therapeutic areas including respiratory disease, bacterial infections and gastrointestinal motility dysfunction.